Large randomised trials and meta-analyses of breast cancer treatments

Lead Research Organisation: Medical Research Council

Abstract

This programme undertakes research to improve the treatment and survival of women with breast cancer by undertaking randomised controlled trials of new and existing treatments and systematically collecting and analysing the data from all breast cancer trials undertaken worldwide. This collaboration meets every few years and involves around 600 trialists. The published findings have had a major impact on cancer research, resulting in new trials to address important treatment questions that had yet to be reliably addressed. An example of such a trial is the ongoing ATLAS trial, which is run from CTSU and involves more than a 1,000 collaborating doctors in 38 countries, has randomised 13,000 women to either 5 or 10 years treatment with tamoxifen, and has shown that longer treatment improves 15 year survival. The published research findings of the collaboration have also had a major impact on the treatment of breast cancer. It has been referenced in evidence-based guidelines worldwide, including those published by the UK National Institute of Clinical Excellence, NICE. While the long-term survival gains identified from the research of the collaboration are each only moderate, the combination of several of these moderate gains have resulted in a halving of breast cancer mortality in the UK for women aged 35-69.

Technical Summary

The programme will continue the long-running Early Breast Cancer Triallists’ Collaborative Group (EBCTCG) and the ATLAS trial follow-up to obtain large-scale randomised evidence about the long-term main effects and side-effects of local and systemic adjuvant breast cancer treatments, and influence the interpretation of past trials and the design of future trials of treatment and screening. About every 5 years, EBCTCG seeks data on each individual patients in all adjuvant breast trials, for checking and meta-analyses and has previously demonstrated effects on mortality not reliably demonstrable in separate trials. EBCTGCG reports (>14,000 citations) influence practice guidelines and change worldwide treatment patterns. The long-term survival gains identified are each only moderate, but, from the combination of several moderate gains, UK breast cancer mortality at age 35-69 has been halved. The collaboration has also shown that 5-year tamoxifen reduces 10-year and 15-year breast cancer mortality rates by 1/3. It was feared that continuing tamoxifen for more than 5 years might increase rather than decrease recurrence, but CTSU’s ATLAS trial (n=13,000) randomised 10-year vs 5-year tamoxifen and showed 10-year continuation moderately lowers 15-year mortality. Follow-up of ATLAS is continuing, as ER+ disease can recur throughout years 10-20.

Organisations

Publications

10 25 50
publication icon
Anderson GM (2018) Breast-Cancer Recurrence after Stopping Endocrine Therapy. in The New England journal of medicine

publication icon
Asselain B (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials in The Lancet Oncology

publication icon
Aznar MC (2018) Exposure of the lungs in breast cancer radiotherapy: A systematic review of lung doses published 2010-2015. in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

publication icon
Bradley R (2021) Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials in The Lancet Oncology

publication icon
Clarke M. (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials in LANCET

publication icon
Collaborative Group On Epidemiological Studies Of Ovarian Cancer (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. in Lancet (London, England)

publication icon
Collaborative Group On Hormonal Factors In Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. in The Lancet. Oncology

publication icon
Davies C (2017) 10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS in The Lancet

publication icon
Davies C (2013) Tamoxifen therapy for patients with breast cancer - Authors' reply. in Lancet (London, England)

publication icon
Davies C (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. in Lancet (London, England)

 
Guideline Title NICE guidelines (CG80) Early and locally advanced breast cancer: Diagnosis and treatment
Description NICE Guideline on the management of early breast cancer
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
Impact EBCTCG is referenced 20 times in the current NICE guideline on the management of early breast cancer.
URL http://www.nice.org.uk/guidance/cg80
 
Guideline Title Scottish Intelligence Guideline Network (SIGN) guideline on treatment of primary breast cancer (SIGN 134)
Description Scottish Intelligence Guideline Network (SIGN) guideline on treatment of primary breast cancer (SIGN 134)
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
Impact EBCTCG is referenced 14 times in the SIGN guideline on the treatment of primary breast cancer
URL http://www.sign.ac.uk/guidelines/fulltext/134/index.html
 
Guideline Title US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Breast Cancer
Description US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Breast Cancer
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact EBCTCG is referenced 6 times in the US National Comprehensive Cancer Network (NCCN) guideline on breast cancer.
URL http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast
 
Guideline Title US National Institutes of Health (NIH) guideline on breast cancer treatment for health professionals
Description US National Institutes of Health (NIH) guideline on breast cancer treatment for health professionals
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact EBCTCG is cited in relation to the different aspects of treatment for early breast cancer (i.e. local therapies and systemic therapies).
URL http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional
 
Description Research grant (ATLAS trial)
Amount £508,000 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 03/2003 
End 12/2015
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation "Floraspe Renzetti" Hospital
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation "Floraspe Renzetti" Hospital
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Alcec - Concepcion del Uruguay
Country Argentina 
Sector Charity/Non Profit 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Alemán Hospital
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Alexander Fleming Institute
Country Argentina 
Sector Charity/Non Profit 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Alexander Fleming Institute
Country Argentina 
Sector Charity/Non Profit 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation All India Institute of Medical Sciences
Country India 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Almirante Nef Naval Hospital
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Almirante Nef Naval Hospital
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Anhui Provincial People's Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Ankara Oncology Hospital
Country Turkey 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Araújo Jorge Hospital
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Arturo Lopez Perez Foundation
Country Chile 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Autonomous University of Barcelona (UAB)
Department Parc Taulí Health Corporation
Country Spain 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Azienda Ospedaliera Spedali Civili di Brescia
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Barzilai Medical Centre
Country Israel 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Base Hospital
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Base Hospital
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Belvedere Medical Corporation
Country United States 
Sector Private 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Benedictine Hospital
Country United States 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Beskids Oncology Centre
Country Poland 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Beth Israel Deaconess Medical Center
Country United States 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Bordet Institute
Country Belgium 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Box Hill Hospital
Country Australia 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Brazilian Institute of Cancer Control (IBCC)
Country Brazil 
Sector Charity/Non Profit 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Brazilian Institute of Cancer Control (IBCC)
Country Brazil 
Sector Charity/Non Profit 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Cancer Centre of Excellence
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Carabineros Hospital
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Cardiovascular Institute of Rosario (ICR)
Country Argentina 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Cathay General Hospital
Country Taiwan, Province of China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Celestino Hernandez Robau Hospital in Santa Clara
Country Cuba 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Central University Hospital of Liege
Country Belgium 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Centro De Enfermedades De La Mama Ltda
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Changhua Christian Hospital
Country Taiwan, Province of China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Chile National Cancer Institute (Instituto Nacional del Cáncer)
Country Chile 
Sector Public 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Chinese Academy of Medical Sciences (CAMS)
Country China 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Città di Castello Hospital
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Civil Hospital of Senigallia
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Civil Hospital of Senigallia
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Clinic Las Condes
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Clinical Hospital of the El Teniente Health Foundation
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Clinical Hospital of the El Teniente Health Foundation
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Coastal Cancer Centre
Country United States 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Concepcion Diagnostic Centre
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Concepción Oncoradiology Centre
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Conrado Benitez Garcia Provincial Teaching Hospital Cancer
Country Cuba 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Cukurova University
Department Balcali Hospital
Country Turkey 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Córdoba Private Institute of Radiotherapy (IPR)
Country Argentina 
Sector Private 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Danbury Hospital
Country United States 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Daugavpils Oncological Hospital
Country Latvia 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Doctor Negrin University Hospital of Gran Canaria
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Donostia Unibertsitate Ospitalea
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Dr George Mukhari Hospital
Country South Africa 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Dubbo Base Hospital
Country Australia 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Duran i Reynals Hospital
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Edith Wolfson Medical Center
Country Israel 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation El-Minia Cancer Centre
Country Egypt 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Espases University Hospital
Country Spain 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Evangelismos Hospital
Country Greece 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Evangelismos Hospital
Country Greece 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Ferdinando Veneziale Isernia Hospital
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation First People's Hospital of Chaohu
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Frederick Memorial Hosp, Frederick, US
Country United States 
Sector Charity/Non Profit 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Freeman Health System
Country United States 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Frere Hospital
Country South Africa 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Frere Hospital
Country South Africa 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Fujian Provincial Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Ganzhou People's Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Ganzhou People's Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Geelong Hospital
Country Australia 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation General Hospital De Jerez De La Frontera
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation General Teaching Hospital in Prague
Country Czech Republic 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation German Clinic of Santiago
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Gertsen Moscow Research Oncology Institute
Country Russian Federation 
Sector Charity/Non Profit 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Gertsen's Institute of Oncology
Country Russian Federation 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Government Medical College, Kottayam
Country India 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Government Medical College, Kottayam
Country India 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Government of Colombia
Department National Cancer Institute
Country Colombia 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Groote Schuur Hospital
Country South Africa 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Groote Schuur Hospital
Country South Africa 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Gualeguaychú Clinical and Oncology Centre
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Gujarat Cancer & Research Institute
Country India 
Sector Charity/Non Profit 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hacettepe University
Department Hacettepe University Cancer Institute
Country Turkey 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hacettepe University
Country Turkey 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hainan Provincial People's Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hainan Provincial Women and Children Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Healthcare Consortium of Garraf (CSG)
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Heilongjiang Province Cancer Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Heilongjiang Province Cancer Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hermanos Ameijeiras Hospital
Country Cuba 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hermanos Ameijeiras Hospital
Country Cuba 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hiroshima University
Department Research Institute for Nuclear Medicine and Biology
Country Japan 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hosp Dr Luiz Antonio
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hosp Dr Luiz Antonio
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital 12 de Octubre
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital 12 de Octubre
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Amstelland
Country Netherlands 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Angeles Clinica Londres
Country Mexico 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Argerich
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Argerich
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Barros Luco Trudeau
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Barros Luco Trudeau
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Base of Osorno
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Base of Valdivia
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Centre Etterbeek-Ixelles
Country Belgium 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Comarcal de Blanes
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Comarcal de Blanes
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Dipreca
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Dipreca
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Doctor Luis Tisne
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Durans I Reinals
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Escuela Eva Perón
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Español
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Evaldo Foz
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Evaldo Foz
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General De Manresa Heliport
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General De Manresa Heliport
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General San Jorge of Huesca
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General San Jorge of Huesca
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General de Catalunya
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General de Ciudad Real
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General de Ciudad Real
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General de Granollers
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General de Granollers
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General de Vic
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital General de Vic
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Intendente Gabriel Carrasco
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Interzonal General de Agudos “Eva Perón"
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Interzonal General de Agudos “Eva Perón"
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Italiano Garibaldi Rosario
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Italiano de La Plata
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Italiano de La Plata
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Jerez de la Frontera
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital La Serena
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital La Serena
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Marcial Quiroga
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Marcial Quiroga
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Mater Dei
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Mater Dei
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Materno-Infantil
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Militar Central
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Militar de Santiago
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Militar de Santiago
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Moinhos de Vento, Porto Alegre
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Moinhos de Vento, Porto Alegre
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Napoleão Laureano, Joao Pessoa
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Napoleão Laureano, Joao Pessoa
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Naval Puerto Belgrano
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Oncológico “Conrado Benítez”
Country Cuba 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Provincial de Rosario
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Público Provincial De La Misericordia
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Público Provincial De La Misericordia
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional Concepción
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional Concepción
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional Dr. Juan Noé
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional Dr. Juan Noé
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional Universitario de Málaga
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional Universitario de Málaga
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional de Antofagasta
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional de Antofagasta
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional de Rancagua
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional de Rancagua
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional de Talca
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional de Talca
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Regional de Temuco
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Rivadavia
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Roy H. Glover
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital San Bernardo
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital San Borja-Arriaran
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital San Borja-Arriaran
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital San Juan de Dios
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital San Juan de Dios
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Sant Jaume de Calella
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Sant Joan de Deu
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Santa Maria
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Santa Maria
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Son Espases
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital São Marcos
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital São Marcos
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Sótero del Río
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Sótero del Río
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Teresa Herrera
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Universitario Insular de Gran Canaria
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Universitario Puerta de Hierro
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Virgen de la Salud
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Virgen de la Salud
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Virgen del Camino
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital Virgen del Camino
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital d'Igualada
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital d'Igualada
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital das Clinicas da UFMG
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital das Clinicas da UFMG
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital das Clínicas Samuel Libânio
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital das Clínicas Samuel Libânio
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital de León
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital de León
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital de Mataro
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital de Mataro
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital de Sant Pau
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital de Sant Pau
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital del Mar
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital del Mar
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital del Salvador
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital del Salvador
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital las Higueras
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hospital of Cancer of Pernambuco
Country Brazil 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation House Of Health Valdese
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation House Of Health Valdese
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Hubei Cancer Hospital (HBCH)
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation IKARUS Project (Incidence of Skeletal Related Events in Breast Cancer)
Country Czech Republic 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Inner Mongolia Medical College Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Institute Rotary Cancer Hospital
Country India 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Institute Rotary Cancer Hospital
Country India 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Institute of Oncology and Rehabilitation
Country Czech Republic 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Instituto Dr Estevez SA
Country Argentina 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Iris Sud Hospital
Country Belgium 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Istanbul University
Department Faculty of Medicine
Country Turkey 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Istanbul University
Department Institute of Oncology
Country Turkey 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Istanbul University
Department Institute of Oncology
Country Turkey 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Jablonec nad Nisou Hospital
Country Czech Republic 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Jawaharlal Nehru University, India
Country India 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Jiangxi Province Cancer Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Jichi Medical University
Country Japan 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Jihlava Hospital
Country Czech Republic 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Kaohsiung Medical University
Country Taiwan, Province of China 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Kaohsiung Medical University
Country Taiwan, Province of China 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Kaplan Hospital
Country Israel 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Karnatak Cancer Therapy & Research Institute
Country India 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Karnatak Cancer Therapy & Research Institute
Country India 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Kaunas Medical University Hospital
Country Lithuania 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Keio University
Country Japan 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation King George's Medical University
Country India 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Krakow Central Oncology Brance
Country Poland 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Královské Vinohrady University Hospital
Country Czech Republic 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Kumamoto Central Hospital
Country Japan 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Kutná Hora Hospital
Country Czech Republic 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Las Dalias Clinic
Country Chile 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Las Higueras Hospital
Country Chile 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Leningrad Oncological Dispensary
Country Russian Federation 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Liaoning Provincial People's Hospital
Country China 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Liepaja Oncological Hospital
Country Latvia 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Lismore Base Hospital
Country Australia 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Lismore Base Hospital
Country Australia 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Liverpool Hospital
Country Australia 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Lower Silesian Oncology Center
Country Poland 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Lozano Blesa University Clinical Hospital
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Lozano Blesa University Clinical Hospital
Country Spain 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation MNJ Institute of Oncology
Country India 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Madras Cancer Institute (WIA), Chennai
Country India 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Maggiore Civil Hospital
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Marcianise Civil Hospital
Country Italy 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Maria Curie Provincial Teaching Cancer Hospital
Country Cuba 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Masaryk Memorial Cancer Institute (MMCI)
Country Czech Republic 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Masaryk Memorial Cancer Institute (MMCI)
Country Czech Republic 
Sector Hospitals 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Masarykova nemocnice, usti nad Labem, Czech Republic
Country Czech Republic 
Sector Academic/University 
PI Contribution ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer.
Collaborator Contribution Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS.
Impact Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years.
Start Year 2006
 
Description Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial 
Organisation Masarykova nemocnice, usti nad Labem, Czech Republic